Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.920
+0.100 (2.07%)
Jun 29, 2026, 1:38 PM EDT - Market open
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
$491,849
Profits / Employee
-$1,081,343
Market Cap
85.60M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Heron Therapeutics | 128 |
| Adicet Bio | 102 |
| Cardiff Oncology | 31 |
| Entera Bio | 22 |
| iBio, Inc. | 20 |
| LeonaBio | 19 |
| Rallybio | 14 |
| MAIA Biotechnology | 13 |
ATHE News
- 13 days ago - Alterity Therapeutics assumed with a Buy at Ladenburg - TheFly
- 13 days ago - Alterity Therapeutics Slides: Corporate presentation - Filings
- 19 days ago - Alterity Aligns With FDA On Phase 3 Design For ATH434 In Treating Multiple System Atrophy - Nasdaq
- 20 days ago - Alterity Therapeutics (ATHE) Gets FDA Nod for Phase 3 Program - GuruFocus
- 20 days ago - Alterity Therapeutics (ATHE) Secures FDA Agreement for Phase 3 ATH434 Trial - GuruFocus
- 20 days ago - Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA - TheFly
- 20 days ago - Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy - GlobeNewsWire
- 26 days ago - Alterity Therapeutics management to meet with BTIG - TheFly